An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial-Reference-Cited by-同舟云学术

An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial

Published:2018-06 Issue: Volume:200 Page:17-23
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Lopes Renato D.,Vora Amit N.,Liaw Danny,Granger Christopher B.,Darius Harald,Goodman Shaun G.,Mehran Roxana,Windecker Stephan,Alexander John H.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study;Chugh;Circulation,2014

2. Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study

3. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions;Capodanno;Circ Cardiovasc Interv,2014

4. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention;Rubboli;Coron Artery Dis,2007

5. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry;Wang;Am Heart J,2008

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI;Journal of the American College of Cardiology;2024-09

2. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS);European Heart Journal;2024-08-30

3. Spectrum of Non-Obstructive Coronary Artery Disease and Its Relationship with Atrial Fibrillation;Journal of Clinical Medicine;2024-08-21

4. Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data;American Journal of Cardiovascular Drugs;2024-08-05

5. Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial;The American Journal of Medicine;2024-06